P2Y12 Inhibition in Patients Requiring OraláAnticoagulation After PercutaneousáCoronary Intervention: The SWAP-AC–2 Study
L Ortega-Paz, W Bor, F Franchi… - JACC: Cardiovascular …, 2024 - Elsevier
Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
[PDF][PDF] De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy
MC Kim, SG Ahn, KH Cho, DS Sim, YJ Hong… - …, 2023 - pcronline.com
Background: The benefits of de-escalation of P2Y12 inhibition after percutaneous coronary
intervention (PCI) may differ by high bleeding risk (HBR) status. Aims: We investigated the …
intervention (PCI) may differ by high bleeding risk (HBR) status. Aims: We investigated the …
Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a …
LR Jackson, C Ju, M Zettler, JC Messenger… - JACC: Cardiovascular …, 2015 - jacc.org
Objectives: The purpose of this study was to determine whether bleeding risk varies
depending on which P2Y12 receptor inhibitor agent is used. Background: Prior studies have …
depending on which P2Y12 receptor inhibitor agent is used. Background: Prior studies have …
P2Y12 inhibitor monotherapy with clopidogrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention
PW Chen, WH Feng, MY Ho, CH Su… - Journal of Clinical …, 2020 - mdpi.com
Background: P2Y12 inhibitor monotherapy is an alternative antiplatelet strategy in patients
undergoing percutaneous coronary intervention (PCI). However, the ideal P2Y12 inhibitor …
undergoing percutaneous coronary intervention (PCI). However, the ideal P2Y12 inhibitor …
[HTML][HTML] Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation
A Goedel, KA Fiedler, J Mehilli… - …, 2019 - eurointervention.pcronline.com
Aims: Clopidogrel is the P2Y 12 inhibitor of choice in patients who undergo PCI and have an
indication for oral anticoagulation (OAC). Prediction of the bleeding risk is of major interest in …
indication for oral anticoagulation (OAC). Prediction of the bleeding risk is of major interest in …
Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale
J Luijkx, P Winkler, A van 't Hof - Future Cardiology, 2022 - Taylor & Francis
The combination of oral anticoagulants with platelet inhibitors has been widely investigated
in patients with coronary stenting and concomitant atrial fibrillation. In these patients, default …
in patients with coronary stenting and concomitant atrial fibrillation. In these patients, default …
Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus …
NJ Verlinden, JC Coons, CJ Iasella… - Journal of …, 2017 - journals.sagepub.com
Background: Triple antithrombotic therapy is used in patients who require systemic
anticoagulation and undergo percutaneous coronary intervention (PCI) requiring dual …
anticoagulation and undergo percutaneous coronary intervention (PCI) requiring dual …
High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary …
JL Ferreiro, D Vivas, JM De La Hera, AL Marcano… - Thrombosis …, 2019 - Elsevier
Introduction There is compelling evidence supporting the association between high on-
treatment platelet reactivity (HPR) and low on-treatment platelet reactivity (LPR) to …
treatment platelet reactivity (HPR) and low on-treatment platelet reactivity (LPR) to …
Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: insights from the …
S Sra, MK Tan, SR Mehta, HN Fisher, JP Dery… - American Heart …, 2016 - Elsevier
Background Since the introduction of newer, more potent P2Y 12 receptor inhibitors (P2Y 12
ris), practice patterns and associated clinical outcomes in patients with myocardial infarction …
ris), practice patterns and associated clinical outcomes in patients with myocardial infarction …
Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant …
H Kitahara, K Tateishi, Y Shiko, Y Inaba, Y Kobayashi… - Plos one, 2022 - journals.plos.org
Background Triple antithrombotic therapy, including dual antiplatelet therapy and oral
anticoagulant (OAC), is recommended for a short-term period after percutaneous coronary …
anticoagulant (OAC), is recommended for a short-term period after percutaneous coronary …